Benefits Think Healthcare is a problem. This employer has a solution
Asking difficult questions, pushing for transparency, and challenging how prices are set have helped a healthcare provider offer better coverage to its employees.
Pharmacy benefits
White Paper Achieving alignment with your pharmacy benefits manager
New research: How employers are approaching pharmacy benefit management and the outcomes reported by organizations that have already moved to these PBMs.
By
will
On-Demand Web Seminar The hidden cost driver your pharmacy strategy is missing: Taking control of specialty infusion spend
Why medical specialty drugs are outpacing pharmacy spend, and what self-funded employers can do about it.
Benefits Think Rewriting the PBM playbook: Exposing hidden costs and empowering plan sponsors
Part one of this two-part series looks at the background, transparency solutions and how to understand PBM profitability.
On-Demand Web Seminar The next era of pharmacy benefits: New research on transparency, satisfaction, and experience
With the current high-cost and high-pressure prescription drug landscape, employers are being forced to rethink how they manage pharmacy benefits – everything from the procurement process to evaluating ongoing service levels, performance, and costs. For many, this may mean shifting from a traditional pharmacy benefits manager (PBM) model to a transparent PBM model.
Benefits Think Rethinking employer coverage for high-cost medications
Direct-to-employer carve-outs can make drugs like GLP-1s more affordable for companies and more accessible for employees.
Exclusive research: Benefit leaders face a pharmacy cost crisis in 2026
Pharmacy cost management is one of the toughest challenges employers will face in 2026, according to new data from Employee Benefit News.
White paper Transparency and innovative cost-containment strategies are the keys to reducing pharmaceutical costs
HR and benefits leaders have a significant opportunity to expand their playbooks with proven methods to overcome their most intractable challenge.
Coalition PBMs: Bigger isn’t always better
Without the right contractual terms in place, hidden costs may mar pooled purchasing power at the expense of employer clients.
UnitedHealth will reimburse pharmacies more for brand-name drugs
The incentives to encourage non-generic brands will encourage pharmacies to keep them in stock and increase their profits, says UnitedHealth's CEO.
Benefits Think Evolving assaults on ERISA preemption threaten benefits uniformity
Laws such as Florida's Prescription Drug Reform Act could unravel many of the invaluable protections ERISA has provided.
Dillon Clair
The ERISA Industry Committee
Podcast Trends impacting self-funding and stop loss – now and into 2024
Learn about Stop Loss industry claim trends, including the impact of gene and cell therapies, and how they are affecting claim costs for self-funded employers.
Podcast Biologics and benefit plans: What employers need to know
Biologics are one of the fastest growing category of drugs—and one of the most expensive—making it challenging to balance cost with safety and efficacy. And it's even more challenging to incorporate unbranded biologics and biosimilars into benefits plans.
How this company is guaranteeing the lowest drug prices
Here’s how healthcare company, Capital Rx, is bringing pharmacy benefit management solutions to consumers in the wake of rapidly increasing drug costs.
Is the pharmaceutical industry due for change?
Should employers increasingly consider cutting out the middle man in the prescription drug procurement pipeline?
Benefits Think Specialty drug conflicts of interest: Employers must act now to control the chaos
In order to maximize the plans fiduciary responsibilities, a contract with appropriate terms and definitions must be in place to allow the plan to exercise their right to carve-out prior authorization.
Denise Giambalvo
Midwest Business Group on Health
CVS Caremark limits the purchase of essential medication to avoid stockpiling
Drugs used to treat chronic conditions are being tried on coronavirus patients; CVS wants to ensure there’s enough to go around.
Benefits Think Health agency reverses course on prescription drug coupon regulations
Following critical feedback and possible IRS conflicts, an HHS FAQ walks back recent pharmacy rules.
Zack Pace
CBIZ
Benefits Think Health agency reverses course on prescription drug coupon regulations
Following critical feedback and possible IRS conflicts, an HHS FAQ walks back recent pharmacy rules.
Zack Pace
CBIZ
Amazon’s battle for corner pharmacy is fought over phone and fax
Drugstore are trying to keep Amazon from wresting away their piece of the $333 billion prescription-drug industry.
